A DNA mutation that occurs frequently in the development of many pancreatic tumors appears to make these cancers vulnerable to an existing type of drug known as PARP inhibitors, according to a new study from scientists in the Perelman School of Medicine at the University of Pennsylvania.![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
![]()
↧